Azitra Inc
AZTRAzitra Inc. is a biotechnology company focused on developing innovative treatments for skin conditions using targeted microbiome modulation and drug delivery technologies. The company aims to address unmet medical needs through its proprietary platform, which focuses on harnessing the skin's microbiome to improve dermatological therapies.
Company News
U.S. stock futures rose ahead of Federal Reserve Chairman Jerome Powell's speech at the Jackson Hole Economic Policy Symposium, with investors anticipating insights on labor market, inflation, and potential interest rate changes.
Quoin Pharmaceuticals reported a net loss of $6.28 per share in Q2 2025, which exceeded analyst estimates. The company is developing QRX003, a topical lotion for Netherton Syndrome, and made significant clinical and regulatory progress while increasing R&D spending.
Enphase Energy reported mixed Q2 results, leading to a rise in its stock price. Several other companies saw significant pre-market movements, both positive and negative, due to various news and earnings reports.
Azitra's stock is trading higher after the company was granted a U.S. patent related to the treatment of atopic dermatitis, a skin condition affecting millions of people in the U.S.
